Purification of yeast isocitrate dehydrogenase [PDF]
The NAD-linked isocitrate dehydrogenase from baker's yeast was purified to homogeneity (as judged by gel filtration and polyacrylamide-gel electrophoresis) with an overall yield of 50% by using dilute solutions of the allosteric effector (AMP) to elute the enzyme specifically from CM-cellulose.
John Illingworth
openalex +4 more sources
Mitochondrial Isocitrate Dehydrogenases from Yeast [PDF]
Abstract A polarographic technique suitable for kinetic studies of either isolated or bound pyridine nucleotide-linked dehydrogenases was used to investigate the isocitrate dehydrogenases of yeast mitochondria. Intact mitochondria were found to contain both triphosphopyridine nucleotide- and diphosphopyridine nucleotide-linked isocitrate dehydrogenases
Carl Bernofsky, Merton Utter
openalex +3 more sources
Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
The identification of heterozygous neomorphic isocitrate dehydrogenase (IDH) mutations across multiple cancer types including both solid and hematologic malignancies has revolutionized our understanding of oncogenesis in these malignancies and the ...
Danielle Golub+2 more
exaly +3 more sources
Isocitrate protects DJ-1 null dopaminergic cells from oxidative stress through NADP+-dependent isocitrate dehydrogenase (IDH) [PDF]
DJ-1 is one of the causative genes for early onset familiar Parkinson's disease (PD) and is also considered to influence the pathogenesis of sporadic PD. DJ-1 has various physiological functions which converge on controlling intracellular reactive oxygen
Woongchang Yoon+2 more
exaly +2 more sources
Differential isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 mutation-related landscape in intrahepatic cholangiocarcinoma. [PDF]
Abstract Background Patients with intrahepatic cholangiocarcinoma (ICC) are prone to recurrence and poor survival. Targeted therapy related to isocitrate dehydrogenase (IDH) is an extremely important treatment.
Xu S+9 more
europepmc +3 more sources
A real-world study of adverse drug reactions of two isocitrate dehydrogenase inhibitor based on the US FDA adverse event reporting system and VigiAccess databases [PDF]
Background and objectivesIsocitrate dehydrogenase (IDH) inhibitor drugs (Enasidenib, Ivosidenib) restore normal metabolism and epigenetic regulation in cells, offering a precision-targeted therapeutic option for acute myeloid leukemia (AML) patients with
Mengmeng Peng+11 more
doaj +2 more sources
Isocitrate Dehydrogenase Inhibitors in Glioma: From Bench to Bedside [PDF]
Isocitrate dehydrogenase (IDH) mutant gliomas are a primary malignancy of the central nervous system (CNS) malignancies, most commonly affecting adults under the age of 55.
Merve Hazal Ser+3 more
doaj +2 more sources
Expression of IDH1, ATRX, p53 in Diagnosis of Gliomas as Per 2016 WHO Classification [PDF]
Introduction: The 2016 World Health Organisation (WHO) classification of tumours of the Central Nervous System (WHO CNS 2016 classification) is used to classify diffuse gliomas as astrocytoma, Oligodendroglioma (ODG), glioblastoma which are three ...
Lokesh Kumar+3 more
doaj +1 more source
Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas. [PDF]
Isocitrate dehydrogenase 1 gene mutations are found in most World Health Organization grade II and III gliomas and secondary glioblastomas. Isocitrate dehydrogenase 1 mutations are known to have prognostic value in high-grade gliomas.
Ming-Yang Li+8 more
doaj +1 more source
Background and Purpose: To quantitatively compare the recurrence patterns of glioblastoma (isocitrate dehydrogenase-wild type) versus grade 4 isocitrate dehydrogenase-mutant astrocytoma (wild type isocitrate dehydrogenase and mutant isocitrate ...
James Stewart PhD+18 more
doaj +1 more source